No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.